Literature DB >> 25574482

Kappa Opioid Receptor Agonist and Brain Ischemia.

Chen Chunhua1, Xi Chunhua1, Sugita Megumi1, Liu Renyu1.   

Abstract

Opioid receptors, especially Kappa opioid receptor (KOR) play an important role in the pathophysiological process of cerebral ischemia reperfusion injury. Previously accepted KOR agonists activity has included anti-nociception, cardiovascular, anti-pruritic, diuretic, and antitussive effects, while compelling evidence from various ischemic animal models indicate that KOR agonist have neuroprotective effects through various mechanisms. In this review, we aimed to demonstrate the property of KOR agonist and its role in global and focal cerebral ischemia. Based on current preclinical research, the KOR agonists may be useful as a neuroprotective agent. The recent discovery of salvinorin A, highly selective non-opioid KOR agonist, offers a new tool to study the role of KOR in brain HI injury and the protective effects of KOR agonist. The unique pharmacological profile of salvinorin A along with the long history of human usage provides its high candidacy as a potential alternative medication for brain HI injury.

Entities:  

Keywords:  Agonist; Brain ischemia; Kappa opioid receptor; Neuroprotective

Year:  2014        PMID: 25574482      PMCID: PMC4285354     

Source DB:  PubMed          Journal:  Transl Perioper Pain Med


  94 in total

1.  Beneficial effects of the kappa opioid receptor agonist U-50488H in experimental acute brain and spinal cord injury.

Authors:  E D Hall; D L Wolf; J S Althaus; P F Von Voigtlander
Journal:  Brain Res       Date:  1987-12-01       Impact factor: 3.252

2.  Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.

Authors:  Feng Yan; Philip D Mosier; Richard B Westkaemper; Jeremy Stewart; Jordan K Zjawiony; Timothy A Vortherms; Douglas J Sheffler; Bryan L Roth
Journal:  Biochemistry       Date:  2005-06-21       Impact factor: 3.162

3.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

4.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

5.  Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats.

Authors:  Zhizheng Zhang; Tsung-Ying Chen; Jeffrey R Kirsch; Thomas J K Toung; Richard J Traystman; Raymond C Koehler; Patricia D Hurn; Anish Bhardwaj
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

6.  Evaluation of neuroprotection and behavioral recovery by the kappa-opioid, PD117302 following transient forebrain ischemia.

Authors:  R F Genovese; J E Moreton; F C Tortella
Journal:  Brain Res Bull       Date:  1994       Impact factor: 4.077

7.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

8.  Properties of a selective kappa agonist, U-50,488H.

Authors:  R A Lahti; P F VonVoigtlander; C Barsuhn
Journal:  Life Sci       Date:  1982 Nov 15-22       Impact factor: 5.037

9.  Evaluation of delayed treatment of focal cerebral ischemia with three selective kappa-opioid agonists in cats.

Authors:  D S Baskin; M A Widmayer; J L Browning; M L Heizer; W K Schmidt
Journal:  Stroke       Date:  1994-10       Impact factor: 7.914

10.  A highly selective kappa-opioid receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro.

Authors:  R D Pinnock
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

View more
  7 in total

1.  Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway.

Authors:  Li-Jie Liu; Jian-Jun Yu; Xiao-Lin Xu
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

Review 2.  Effects of anesthesia on cerebral blood flow, metabolism, and neuroprotection.

Authors:  Andrew M Slupe; Jeffrey R Kirsch
Journal:  J Cereb Blood Flow Metab       Date:  2018-07-16       Impact factor: 6.200

3.  The Role of κ Opioid Receptor in Brain Ischemia.

Authors:  Chunhua Chen; Chunhua Xi; Xuan Liang; Jingyuan Ma; Diansan Su; Ted Abel; Renyu Liu
Journal:  Crit Care Med       Date:  2016-12       Impact factor: 7.598

4.  Intranasal salvinorin A improves neurological outcome in rhesus monkey ischemic stroke model using autologous blood clot.

Authors:  Longfei Wu; Di Wu; Jian Chen; Chunhua Chen; Tianqi Yao; Xiaoduo He; Yanqin Ma; Xinglong Zhi; Renyu Liu; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2020-07-02       Impact factor: 6.200

5.  Diuretic Activity of a Novel Peripherally-Restricted Orally-Active Kappa Opioid Receptor Agonist.

Authors:  Tyler C Beck; Matthew A Hapstack; Gautam S Ghatnekar; Thomas A Dix
Journal:  Med Sci (Basel)       Date:  2019-08-31

6.  κ‑opioid receptor agonist U50488H attenuates postoperative cognitive dysfunction of cardiopulmonary bypass rats through the PI3K/AKT/Nrf2/HO‑1 pathway.

Authors:  Jianing Fan; Long Li; Pengxia Qu; Yugang Diao; Yingjie Sun
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

7.  Neurons derived from human-induced pluripotent stem cells express mu and kappa opioid receptors.

Authors:  Zhi-Hai Ju; Xuan Liang; Yao-Yao Ren; Luo-Wa Shu; Yan-Hong Yan; Xu Cui
Journal:  Neural Regen Res       Date:  2021-04       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.